Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 06, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details specific transactions executed on February 03, 2006, and notified on February 06, 2006, involving the SmithKline Beecham Employee Benefit Trust:
- Share Sale: 3,800 Ordinary shares were sold on behalf of a participant in the GlaxoSmithKline Annual Investment Plan at a price of GBP14.52 per share.
- Share Transfer: 12,794 Ordinary shares were transferred from the Trust to a participant in the GlaxoSmithKline Annual Investment Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the Trust is a discretionary fund for non-US employees and former employees, and that Director Mr. J Heslop holds an interest in the fund shares in the same capacity as other beneficiaries.
Investor Verification Points
- Verify the total number of shares held by the SmithKline Beecham Employee Benefit Trust following these transactions.
- Confirm the specific identity of the Annual Investment Plan participants involved in the sale and transfer.
- Review the full Disclosure Rule 3.1 4R (1) (b) requirements to ensure complete compliance regarding Director Mr. J Heslop's interest.